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Abstract
A recent status on asthmaticus multiple case report by Beute demonstrated the beneficial 
effects of phosphodiesterase III (PDE3) and phosphodiesterase IV (PDE4) inhibition. This 
chapter reviews the possible underlying mechanisms, beside the known effect, for the 
beneficial effects of a mixed PDE3/4 inhibitor in allergic airway inflammation. Structural 
cells of the lung and immune system express PDE3 and 4. PDE3 and 4 inhibition have 
a number of consequences related to physical function and cytokine production. The 
most direct effect of PDE3 inhibition being relaxation of smooth muscle cells results in 
bronchodilation. However, PDE3 inhibition appears to go further than a mere inhibitory 
activity in bronchial smooth muscle. It also affects structural cells, and more importantly, 
it creates an improved barrier function in endothelial cells. PDE3 and 4 inhibition there-
fore strengthens the immune barrier; but in addition, it modifies the cells of the immune 
system itself, as these also express PDE3 and 4 activity, thus changing their function. All 
aspects of asthma-related pathophysiology seem to be affected by PDE3 and 4 inhibition. 
Clinical use of a mixed PDE3/4 inhibitor in respiratory diseases is currently limited to a 
few studies, including life-threatening asthma in which mixed PDE3/4 inhibition has a 
beneficial effect.
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1. Introduction
Asthma is an obstructive airway disease characterized by inflamed airways, structural and 
physiological abnormalities in the airways, and shortness of breath [1]. Important primary air-
way cells are alveolar cells, endothelial cells, and smooth muscle cells; and secondary cells 
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are involved in regulation of innate and adoptive immunology. Conventional treatment with 
inhaled corticosteroids combined with beta-adrenergic agonists supports and induces smooth 
muscle relaxation to reopen the inflamed airways, relieves symptoms, supports inspirational 
and expirational flow, and reduces inflammation [2]. These treatment regimens were also used 
in the extreme severe cases of asthma like status asthmaticus and patients with bronchospasm, 
in some cases with only minimal effect. The treatment goal in these severe cases of acute asthma 
is the prompt relief of respiratory distress. The great benefit of a mixed PDE3/4 inhibitor, in 
these severe cases, is the induction of acute as well as long-lasting bronchodilator effects [3].
At the moment, there is no effective treatment for these severe asthmatic patients [4] and there 
are no clear, effective guidelines. Moreover, treatment of these patients is multidisciplinary, 
involving first aid physicians, intensive care physicians, anesthetists, and pulmonary physi-
cians, requiring golden standards and treatment regimens per hospital for optimal results. There 
are still too many asthma deaths; numbers in US are up to nine cases per day and in the UK are 
up to over three cases per day. Presently, in the Netherlands, there are annually more than 60.
This review discusses the PDE3 gene family and PDE3 inhibition, traditionally used in acute, 
refractory heart failure. We discuss the benefits of combined PDE3 and 4 inhibition in status 
asthmaticus [3], and the possible mechanisms which may be responsible for these beneficial 
effects of PDE3 and 4 inhibition.
2. The PDE superfamily: important regulators of cyclic nucleotide 
signaling pathways and networks
Intracellular signaling via complicated regulatory networks plays a critical role during physi-
ological cellular responses. cAMP and cGMP were the first molecules described as intracel-
lular second messengers [5]. They regulate multiple intracellular targets, including protein 
kinase A and protein kinase G, guanine nucleotide exchange proteins activated by cAMP 
(Epacs), cyclic nucleotide-gated ion channels, and PDE activities [6]. Intracellular concentra-
tions of cAMP and cGMP are regulated through their synthesis by adenylyl cyclases (ACs) 
and guanylyl cyclases and their degradation via cyclic nucleotide PDEs. Ten different ACs 
have been identified and classified into two groups [7]. The first group consists of transmem-
brane enzymes which are activated by different hormones, neurotransmitters, chemokines, 
and cytokines in the G-protein-coupled receptor cascade [8]. Another group of cytosolic ACs 
is regulated by bicarbonate and calcium ions [8]. Whereas, cytosolic ACs are all encoded by 
one gene, transmembrane ACs represent a group encoded by nine different genes [9].
The large PDE superfamily is comprised of 11 PDE gene families (PDE1–PDE11). They spe-
cifically hydrolyze cyclic nucleotides, and can be classified according to their primary struc-
tures, tissue expression, biochemical properties, regulation, and their sensitivity to different 
pharmacological agents [10]. By catalyzing the hydrolysis of cAMP and cGMP, PDEs regulate 
the intracellular concentrations of these critical second messengers, and consequently, their 
downstream signaling pathways and networks. PDEs also function as important regulators 
in the compartmentation of cyclic nucleotide signaling pathways and networks. Individual 
PDEs are targeted/recruited to specific intracellular locations, where they are incorporated 
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into specific multiprotein regulatory complexes (“signalosomes”) through protein-protein 
interactions. By virtue of their localization to specific compartments, PDEs can thus regulate 
specific cyclic nucleotide signaling pathways [11].
3. PDE3 and PDE4
PDE3 is expressed in pulmonary structural cells and cells of the immune system. Lung struc-
tural cells, including smooth muscle cells, epithelial cells, and endothelial cells, express PDE3. 
PDE3A and B are encoded by two highly related and similarly organized genes on human 
chromosomes, 12p12 and 11p15 [12–14]. Both PDE3A and PDE3B hydrolyze cAMP and cGMP, 
with 4–10 times higher affinity (Vmax) for cAMP [15]. Biochemical and histochemical studies 
of the localization of PDE3 suggested that PDE3 was associated with the sarcoplasmic reticu-
lum, Golgi endosome, and nuclear envelope in cardiac tissue [16]. PDE3 plays a major role in 
cardiac contraction by modulating cAMP-dependent phosphorylation of voltage-gated Ca2+ 
channels and Ca2+ entry [17]. In addition, recent studies with PDE3A and PDE3B KO mice 
indicate that PDE3A, not PDE3B, regulates basal contractility in mouse heart [18].
Kass et al. described one mechanism, whereby PDE3 might be functionally modulated by 
cGMP occupying the PDE3 catalytic site [19]. PDE3 binds both cAMP and cGMP at its cata-
lytic site with high affinity, and endogenous cGMP, generated by NO-induced activation of 
guanyl cyclase, can function as a competitive inhibitor of hydrolysis of cAMP by PDE3 [20]. 
NO-induced cGMP/cAMP cross-talk, mediated via cGMP inhibition of cAMP hydrolysis by 
PDE3 which leads to increased levels of cAMP, is thought to mediate some of the effects of NO 
in inflammatory and lung structural cells. NO modulates pulmonary vascular tone, causing 
non-adrenergic-, non-cholinergic-mediated bronchodilation [21]. Overexpression of nitric oxide 
synthase in both endothelial and airway epithelial cells resulted in diminished airway inflam-
mation [22]. Under normal conditions of NO/cGMP signaling, PDE4, with a high Km for cAMP, 
is thought to degrade cAMP because PDE3 with a lower Km for cAMP is inhibited by endog-
enous cGMP and thus can increase cAMP [23]. PDE3-induced vasorelaxation is potentiated 
when NO/cGMP is suppressed as PDE3 inhibition increases both cAMP and cGMP, in which 
cGMP inhibits cAMP degradation. PDE4 inhibition only increases cAMP and thus is unaffected 
by NO/cGMP suppression [23]. PDE3 seems to be more responsible for cAMP degradation at 
low intracellular cAMP concentrations, whereas PDE4 is more important for control of cAMP at 
higher concentrations [24]. This suggests a beneficial effect of NO in allergic airway inflamma-
tion and urges caution in the use of NOS inhibitors [22]. Since the first PDE3 inhibition papers 
in the 1990s, 11 PDE families have been identified, and presently at least four isoforms of PDE4 
are known [25]. Also, the idea of signalosomes has been postulated and partly verified [26].
4. Modulation of structural cells and immune cells by PDE3 and 4 
inhibition
Several structural cells express PDE3. Inhibition of PDEs has a number of consequences in the 
pathophysiology of asthma.
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4.1. Smooth muscle cells and cardiomyocytes
Cardiac muscle tissue and smooth muscles are not under conscious control. The role of 
PDE3 in cardiac muscle and in vascular and bronchial smooth muscle slightly differs due to 
regulation by different modulators and inhibitors [19]. Vascular SMC and airway SMC are 
widely comparable [27]. Reducing cAMP by PDE3 modulates contraction; PDE3 inhibition 
(PDE3i) leads to relaxation of vascular and airway SMC which results in vasodilation and 
bronchodilation due to the elevated levels of cAMP. NO activates soluble- and membrane-
bound guanylate cyclases, which synthesize cyclic guanylate monophosphate (cGMP), which 
subsequently can serve as a competitive inhibitor of PDE3 as well as activator of cGMP pro-
tein kinases [16]. The downstream effects of NO are limited, in part, by phosphodiesterase 
(PDE)-induced degradation of cGMP [28].
The primary mechanism behind the PDE3 regulation of myocardial physiology relates to its con-
trol of cAMP levels; inhibition of myocardial PDE3, especially PDE3A, leads to decreased cAMP 
breakdown, resulting in increased cAMP which mediates positive inotropic effects and increases 
in myocardial contractility [29]. Although PDE3 inhibitors increase myocardial contractility and 
vasodilation in heart failure patients [29], prolonged use of the PDE3 inhibitor milrinone in these 
patients increased mortality was observed, most likely due to arrhythmias and cardiac arrest 
[30]. Presently, milrinone has an approval for short term treatment of untreatable exacerbations 
of heart failure and as a chemical “bridge to transplant” [31]. The work of Chen Yan and her 
colleagues suggests that the untoward effects of chronic administration of relatively high dosis 
of milrinone may possibly be related to long term effects of cAMP on pathological remodeling 
and progression of heart failure [32], via upregulation of inducible cAMP early repressor (ICER) 
and subsequent increases in cardiomyocyte apoptosis [33]. According to this hypothesis, PDE3 
inhibitors increase cAMP, leading to increased expression of ICER, which blocks transcription of 
PDE3. This cascade of events induced a pathological “feedback loop,” with downregulation or 
inhibition of PDE3 leading to increased cAMP/PKA signaling, upregulation of ICER, continued 
downregulation of PDE3, and enhanced apoptosis in cardiaomyocytes [33].
In smooth muscle cells, increased cGMP levels induce vasorelaxation. Due to effects of PDEs 
on hydrolysis of cGMP, PDE inhibitors play a major role in the fine-tuned regulation of this 
function. In addition to PDEs, NO plays an important role in vasorelaxation, perhaps, in part, 
by its activation of cytosolic guanylate cyclases, leading to increased production of cGMP, and 
subsequent inhibition of PDE3. The PDE3 inhibitor, cilostazol (Pletal), is widely used to treat 
intermittent claudication (IC), a lower-extremity peripheral arterial disease characterized by 
exercise-/ischemia-induced leg pain. It is thought that cilostazol increases walking distance 
and alleviates IC symptoms by cAMP-mediated vasodilation and inhibition of both platelet 
activation and vascular wall inflammation [34].
Asthma can present itself with varying levels of severity, and a particular subgroup of patients, 
labeled as “severe asthmatics” is characterized by the persistence of symptoms despite therapy 
with corticosteroids [2, 35]. Examination of bronchial airways from patients with severe asthma 
shows a greater amount of ASM (Airway Smooth Muscle) cell mass and of subepithelial fibrosis 
compared to non-severe asthmatics [36, 37]. In ex-vivo studies, ASM cells from severe asthmat-
ics demonstrated increased cell growth and proliferation [38] and an increase in proliferating 
cell nuclear antigen, a marker of proliferation [39]. Cultured ASM cells from mild-to-moderate 
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asthmatics also proliferated faster than ASM cells from normal subjects [40]. Bhavsar et al. have 
previously demonstrated corticosteroid insensitivity in blood monocytes and alveolar macro-
phages from patients with severe asthma compared to those with non-severe asthma [41, 42]. 
Another feature of steroid insensitivity could be the ongoing ASM cell growth because the 
enhanced proliferation of ASM cells from patients with mild asthma is resistant to dexamethasone 
[43]. Given this perspective, it is of interest that studies with VSMC from PDE3A and PDE3B KO 
mice indicated that the absence of PDE3A, not PDE3B, diminished VSMC proliferation and indi-
cated a G0 G1 cell cycle arrest [44]. PDE3 inhibition might reduce ASM proliferation in asthmatics.
4.2. Endothelial cells
Endothelial cells play an important role in the pathophysiology of asthma. Due to the expres-
sion of adhesion molecules, they enable cells to extravasate from the bloodstream into the 
inflamed tissue. Endothelial cells also possess a barrier function to prevent leakage of blood 
fluid in the tissue. Endothelial cells express PDE3 and 4, and inhibition of PDE3 and 4 of 
endothelial cells  inhibited eosinophil and neutrophil adherence to monolayers of endothe-
lial cells [45, 46]. PDE3 and 4 synergistically enhance the inhibition of VCAM1 expression 
and eosinophil adhesion to activated-human lung microvascular endothelial cells [45]. 
Inhibition of PDE3 leads to increases in cAMP which improves endothelial barrier functions 
and supports cell-cell junctions [47]. BW245c, a DP receptor antagonist, increases cAMP, and 
enhanced endothelial barrier function in a cAMP-dependent matter via the DP receptor, a G 
protein coupled receptor [48, 49]. Hyperpermeability of pulmonary endothelial monolayers, 
evoked by thrombin or Escherichia coli hemolysin, can be blocked by the simultaneous activa-
tion of adenylyl cyclase and inhibition of PDEs, especially PDE3 and PDE4 [50]. Sphingosine-
1-phosphate (S1P1) induces endothelial cytoskeletal rearrangement and barrier enhancement 
by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin dependent mechanisms as well 
[51]. In vivo studies with asthma models indicate that compounds such as BW245c, sphin-
gosine 1-phosphate receptor agonist (FTY720), and prostacyclin-2 analog (iloprost) impair 
Dendritic Cell (DC) migration [52–54]. This can be explained by a direct effect of these com-
pounds on improving endothelial cell barrier function via elevated levels of cAMP [48, 55], 
which might affect DC migration from tissue to the draining lymph nodes.
PDE inhibition, a therapeutic approach to increase cAMP levels, was beneficial in treating 
capillary leakage and edema in a rat model of systemic inflammation induced by LPS [56]. 
Moreover, PDE3 inhibition was compared to dobutamine treatment (β-adrenoreceptor com-
pounds); the former showed inotropic, lusitropic, and vasodilating properties which were not 
seen in patients treated with dobutamine [57, 58]. In bypass surgery patients, reduced inflam-
matory responses were observed during PDE3 inhibition compared to placebo treatment [59]. 
Furthermore, reduced TNF-α-levels, a cytokine which is increased in sepsis, were observed 
during PDE3 inhibition by enoximone compared to dobutamine-treated septic patients [58].
Hydrogen peroxide (H
2
O
2
), derived from neutrophils and other cells, supposedly is impor-
tant in the development of vascular injury and thus of pulmonary edema. In a porcine pulmo-
nary artery endothelial cell monolayer model, H2O2 increased hydraulic conductivity while 
selectivity was decreased. It is known that certain inhibitors of PDE isoenzymes 2, 3, and 
4 could block H
2
O
2
-induced endothelial permeability [60]. The data suggest that adenylate 
cyclase activation/PDE inhibition is a powerful approach to block H
2
O
2
-induced increase in 
Phosphodiesterase 3 and 4 Inhibition: Facing a Bright Future in Asthma Control
http://dx.doi.org/10.5772/intechopen.74309
91
endothelial permeability. This concept appears especially valuable when endothelial PDE iso-
enzyme patterns and PDE inhibitor profiles are matched optimally [61].
4.3. Epithelial cells, pneumocyte type I and type II
Human epithelial cells express PDE3 [62]. NO and cAMP both modulate membrane water 
permeability via aquaporin5 expression in pneumocyte type I [63, 64]. Experimental lung 
edema can be attenuated by selective PDE3 and PDE4 inhibitors [50, 65–67]. In experimental 
pulmonary edema, PDE3 inhibition reduces the numbers of inflammatory cells in BAL [66]. In 
alveolar epithelial cells, LPS-induced biosynthesis of proinflammatory cytokines is regulated 
by cAMP and tightly controlled by PDEs, and can be reduced by PDE inhibitors [68].
Inhibition of PDE3 and elevation of cAMP improve epithelial and endothelial barrier func-
tion and reduce SMC proliferation, which are interesting therapeutic targets in the future for 
asthma.
5. Immune cells
Mechanisms for regulation of PDE3 activity in immune cells, including dendritic cells, mono-
cytes, B-cells, NK cells γδT cells, αβT-cells, T-cells, macrophages, eosinophils, and neutrophils, 
all of which express PDE3 isoforms are largely unknown (immgen database http://www.imm-
gen.org/databrowser/index.html). Theophylline is a nonspecific PDE inhibitor [69]. In asth-
matic patients, the inflamed airway mucosa, characterized by the presence of eosinophils, IgE 
positive mast cells, T-cells and dendritic cells, exhibits dysregulated barrier immunity [70]. 
These various inflammatory cells each have their own position in the asthma cascade. PDE3 
and PDE4 are the major isoenzymes regulating IgE-stimulated mediator release from rat peri-
toneal mast cells [71]. Alveolar macrophage activation can be inhibited by PDE3/PDE4 inhibi-
tors [72]. DC cultures were treated with a PDE4 inhibitor and with combined inhibition of 
PDE3 and 4; the latter resulted in a two times stronger reduction in LPS-induced TNFα release 
in DC cultures [73]. In vitro inhibition of PDE4 in DCs resulted in reduced development of Th1 
cells as measured in reduced capacity to produce IL-12p70 and TNFα upon LPS or CD40L 
stimulation [74]. Peripheral blood monocytes from atopic dermatitis patients and healthy con-
trols show inhibition of LPS-induced TNFα release during treatment with PDE4 inhibitors [75].
Inhibition of PDE3 and PDE4 prevents immunogen-stimulated IL-2 release from CD4 and CD8 
human T-cells. Human T-cells and B-cell express PDE3 [73, 76–78]. Knock down strategies 
or inhibitors of PDE4B or D inhibit IL-4, IL-5, and IFNγ expression or production [79–81]. 
Peripheral blood mononuclear cells from atopic dermatitis patients and healthy controls show 
inhibition of PMA-induced proliferation due to the treatment with PDE4 inhibitors. cAMP 
was found to inhibit T-cell proliferation and differentiation which was linked to IL-2 [82, 83]. 
IL-2 activation of CD25+ T cells (Treg cells) led to a drastic upregulation in AC activity and 
to cAMP accumulation; an opposite significant decrease in AC activity was seen in CD25− 
T cells [83]. The PDE activity remained unchanged in both cell subpopulations, suggesting 
that the mechanism of cAMP accumulation in stimulated Treg involves AC7 activation [83]. 
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Cyclic AMP is a pleiotropic regulator of cell growth and function. In T-cells, cAMP suppresses 
TCR-triggered proliferation and cytokine production. cAMP is also a selective modulator of 
the actions of the proinflammatory transcription factor NF-κB. NF-κB plays a crucial role in 
switching on the gene expression of inflammatory and immune mediators and is therefore an 
important target for therapy [84]. cAMP is an important negative regulator of T cell activa-
tion, and increased levels of cAMP are associated with T cell hyporesponsiveness in vitro [85]. 
Stimulation of mouse CD4 T-cells by immature allogeneic DC combined with a PDE3 inhibitor 
resulted in functional Foxp3+ T-cells that delayed allograft rejection [86]. Moreover, PDE3 inhi-
bition results in functional human Foxp3+ CD4+ T-cells which are driven by allogeneic APCs. 
The mechanism for these responses seems to be related to demethylation of FoxP3 gene [86]
Treatment with S-Petasin, an inhibitor of PDE3 and 4, reduced eosinophilic airway inflammation 
in an OVA model for asthma [87]. Although eosinophils do not express PDE3, reduced inflamma-
tion might be an indirect consequence of elevated levels of cAMP in endothelial cells that enhance 
endothelial barrier function and lowered the expression of adhesion molecules [45, 47]. PDE3 
inhibitors sustained increased levels of cAMP in mast cells which are inhibitory to both baso-
phils and human lung mast cells function [88]. Rat peritoneal mast cells showed reduced IgE-
stimulated mediator release when treated with PDE3 inhibitors [71]. The conductive players in 
asthma, including T-cells and DC, and the central effector cells in asthma, including eosinophils, 
mast cells, basophils and neutrophils, can be targeted directly or indirectly with PDE3 inhibitors.
Recently, more and more interest is seen for the “old” theophylline which is a broad PDE inhibi-
tor [69]. Theophylline [69] is a drug which targets PDE4 and, at high doses, also PDE3. However, 
it is a relatively weak bronchodilator at therapeutic concentrations. In patients, it is beneficial; 
and addition of theophylline can improve asthma control to a greater extent than beta2-agonist 
in patients with severe asthma [89]. Furthermore, in asthma patients poorly controlled by ste-
roids, low dose theophylline added to inhaled corticosteroids improves asthma control [69]. 
The proposed mechanisms of action of theophylline include nonselective inhibition of PDE, 
antagonism of Adenosine receptors, inhibition of nuclear translocation of NF-κB, improved his-
tone diacetylase 2, improved IL-10 secretion, induction of apoptosis of inflammatory cells (neu-
trophils and eosinophils) [90, 91], and inhibition of T-cell proliferation [85]. These features are 
of significant importance for severe asthma with poor steroid control, in which neutrophils are 
found and these patients were difficult to treat [4]. Theophylline exerted proapoptotic effects on 
monocyte-derived dendritic cells (DCs) and impaired DCs differentiation [90, 91].
6. PDE3 and 4 inhibition in the context of asthma
There is little literature available regarding enoximone in the context of airway disease. Bethke 
et al. showed that enoximone has inhibitory capacity on PDE3 and PDE4 [92]. Fujimura et al. 
researched cilostazol as a PDE3 inhibitor in asthma, showing its beneficial effect on bronchial 
hyper-responsiveness in elder asthmatics [93]. PDE4 inhibitors have been described in pre-
clinical and clinical settings in the context of lung diseases like asthma and COPD [94, 95]. 
The PDE4 inhibitor roflumilast inhibits TGFβ-induced connective tissue growth factor (CTGF), 
collagen I and fibronectin in airway smooth muscle (ASM) cells of bronchial tissue rings [96]. 
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Roflumilast is approved as part of the treatment regimen for Chronic Obstructive Pulmonary 
Disease (COPD) [97]. PDE3 inhibitors, including cilastozol, milrinone, and mixed PDE3/4 
inhibitor enoximone, have mainly been used in the context of heart failure. Literature pro-
vides several cases with adverse effect and fatal outcome in the use of high dose PDE inhibi-
tors for the chronic treatment of severe heart failure. A reason for this unfavorable outcome 
might have been that enoximone in heart failure was given in exceedingly high doses up to 
2400 mg daily (31 mg/kg/dd) [98–100]; doses which were found to be extremely likely to cause 
severe side effects and a high mortality rate: after 6 months of treatment, at least half of the 
patients had died. Thus, the early research in pulmonary use has been abandoned and, since 
the late 90s, the sparse research into use of PDE3-inhibitors for pulmonary purposes has not 
led to the use of any of these drugs in the treatment of asthma. The first paper addressing 
actual clinical cases, in which enoximone treatment was given successfully in status asth-
maticus and near fatal asthma was Beute [3], inspired by the resemblance between vascular 
and bronchial smooth muscle cell relaxation. In this paper, the doses used were considerably 
lower (1.15 mg/kg single dose) and the duration of administration was substantially shorter 
than in heart failure. Here, enoximone proved to be beneficial without side effects.
Enoximone is known as a PDE3 inhibitor that increases levels of cAMP as well as cGMP; how-
ever, in those cells where both compounds are present, cGMP will act as a competitive inhibi-
tor on the breakdown of cAMP, thereby sustaining elevated levels of cAMP. cGMP can also 
be generated by nitric oxide (NO)-induced stimulation of guanylylcyclase (both abundantly 
present in smooth muscle cells), again impairing the breakdown of cAMP. The IC50 values of 
enoximone for PDE3 and PDE4 are 5.9 and 21.1 μM. The affinity of PDE3 for cAMP is 20 times 
higher than that of PDE4 [101].
These mechanisms probably allow for the favorable outcome of the relatively small doses of 
enoximone in Beute [3] and suggest an effect that exceeds its half-life.
Smooth muscle relaxation is more pronounced after administration of selective PDE3 inhibi-
tors compared with PDE4 inhibitors. PDE3 inhibition leads to the enhancement of relaxation 
evoked by β2-receptor stimulation. Furthermore, simultaneous administration of siguazodan 
(PDE3 inhibitor) and rolipram (PDE4 inhibitor) enhances this relaxation, [102].
In Figure 1, both PDE3 and 4 are important in tailoring cyclic adenosine monophosphate sig-
naling. PDE3/4 inhibitor increases intracellular cyclic adenosine monophosphate levels and 
has anti-inflammatory effects. Activation of a G-protein-coupled receptor (GPCR) activates 
adenylyl cyclase (AC) resulting in the induction of cAMP with the consequence of phospho-
kinase A (PKA) activation. Effect of PDE3/4 inhibition causes bronchodilation and improves 
endothelial and epithelial barrier function.
PDE4 is also present alongside the PDE3 isoenzyme in airway smooth muscle; the PDE3 iso-
enzyme is considered to predominate in airway smooth muscle, and inhibition of this enzyme 
leads to airway smooth muscle relaxation [103]. Moreover, PDE3 isoenzyme A is located in 
the cell membrane [25] and presumably easy to target, and could be involved in the rapid 
effects of therapy (minutes or earlier) seen during the intravenous emergency treatment in 
the studies of Beute [3].
Bringing to mind once again that all the cells and mechanisms mentioned in this chapter are 
regulated/influenced by either PDE3, PDE4, or both, and that all these cells and mechanisms 
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are involved in the development, maintenance, or aggravation of asthma, there is a strong 
case for the assumption that enoximone may have a large impact on the acute treatment of 
severe asthma, on various separate levels. Additional safety studies will also be required.
As discussed above, further research in PDEs appears to be advisable in order to investigate 
their true potential.
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